Veradermics reported positive results from a late-stage Phase 2/3 trial of its oral hair-loss therapy VDPHL01 in men with mild-to-moderate pattern hair loss. The company said participants taking the pill once or twice daily achieved about 30–33 additional hairs per square centimeter over six months versus roughly seven additional hairs in the placebo group. Veradermics also reported high response rates by participant and investigator assessment, including 79%–86% of men reporting improvement and 72%–84% of clinical trial investigators noting improvement. With the therapy in a public-company setting, attention will turn to next steps toward potential registration and differentiation versus topical or device-based options. The late-stage dataset adds to the competitive pressure in male pattern hair restoration, where differentiation often depends on duration of effect, safety, and dosing convenience.